June 15, 2016 (Shareholders Foundation) - An investigation on behalf of investors of Ocular Therapeutix Inc (NASDAQ:OCUL) shares over potential securities laws violations by Ocular Therapeutix and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Ocular Therapeutix Inc (NASDAQ:OCUL) concerning whether a series of statements by Ocular Therapeutix regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Shares of Ocular Therapeutix Inc (NASDAQ:OCUL) reached as high as $42.95 per share in March 2015. Since then NASDAQ:OCUL shares lost significant value and traded as low as $5.47 per share in January 2016.

On June 6, 2016, Ocular Therapeutix Inc announced topline results from its second Phase 3 clinical trial to evaluate the safety and efficacy of DEXTENZA (sustained release dexamethasone) Intracanalicular Depot for the treatment of ocular itching associated with chronic allergic conjunctivitis.

Shares of Ocular Therapeutix Inc (NASDAQ:OCUL) declined from $12.43 per share on June 3, 2016 to as low as $6.26 per share on June 10, 2016.